SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
Trial details
- Registry ID
- NCT07187531
- Drugs studied
- High Dose SAB-142, Low Dose SAB-142
TrialRedline tracks 2 clinical trials sponsored by SAb Biotherapeutics, Inc.: 2 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 DiabetesNCT07187531 | High Dose SAB-142, Low Dose SAB-142 | Recruiting | 2027-11Estimated |
| Study of SAB-176 in Healthy Adult ParticipantsNCT04850898 | SAB-176 | Completed | 2021-10-08Actual |
Names as written in the registry records.
NCT07187531 · SAb Biotherapeutics, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Part A: Incidence of treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), and serious adverse events (SAEs) Measure: Part B: Area under the concentration-time curve (AUC) of C-peptide after a 2 hour mixed meal tolerance test (MMTT). After: Measure: Part A: Incidence of treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), and serious adverse events (SAEs) Measure: Part B: Area under the concentration-time curve (AUC) of C-peptide after a 2 hour mixed meal tolerance test (MMTT) Measure: Part C: Area under the concentration-time curve (AUC) of C-peptide after a 2-hour mixed meal tolerance test (MMTT)..
NCT07187531 · SAb Biotherapeutics, Inc.
Before: Not yet recruiting. After: Recruiting.